Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation as Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma

NCT04121507 is registered in ClinicalTrials.gov with GWT-TUD GmbH as lead sponsor.

NCT NCT04121507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04121507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation as Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma
Lead sponsor
GWT-TUD GmbH
Phase
Phase 2
Overall status
Completed
Start date
June 24, 2019
Completion date
February 2, 2023
Enrollment
60 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive non-hodgkin lymphoma (anhl), lymphoma, b-cell, lymphoma, t-cell